- Home
- ACH vs OTLK Comparison
ACH vs OTLK Comparison
Compare ACH & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACH | OTLK |
|---|---|---|
| Founded | 1882 | 2010 |
| Country | United States | United States |
| Employees | 6500 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.5M | 249.6M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | ACH | OTLK |
|---|---|---|
| Price | $3.20 | $0.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $3.38 | $2.50 |
| AVG Volume (30 Days) | 567.4K | ★ 13.4M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | $4.43 | $173.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.84 | $0.16 |
| 52 Week High | $4.69 | $3.39 |
Technical Indicators
Market Signals| Indicator | ACH | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 41.12 |
| Support Level | $2.55 | $0.75 |
| Resistance Level | $3.13 | $1.83 |
| Average True Range (ATR) | 0.27 | 0.18 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 16.88 | 18.48 |
Price Performance
Historical ComparisonAbout ACH Accendra Health Inc.
Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.